Jeff Evans - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Jeff Evans's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Jeff Evans
Verified
Editor, Rheumatology News, MDEdge
Raleigh
Beats
Disabilities. Social ServicesMental Health
Content
By Jeff Evans Verified| Medscape Verified closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel News > Medscape Medical News > FDA Approvals The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion, announced today
By Jeff Evans Verified| MDEdge Verified The U.S. Food and Drug Administration has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion, announced today. It is the ninth biosimilar of adalimumab (Humira) to be approved in the United States. Yuflyma is approved for the treatment of adult patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa
Company Info
MDEdge
Parsippany-Troy Hills, New Jersey, United States
+1 240-221-2468